Etoricoxib: Clinical Trials

15 trials of Etoricoxib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 3 unknown, 2 terminated, 1 recruiting. 15 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 215Completed 8, Unknown 3, Terminated 2, Recruiting 1, Withdrawn 1
Phase 12Completed 1, Unknown 1

Follow Etoricoxib: new trials by email Literature Review of Etoricoxib trials Research Report on Etoricoxib

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Etoricoxib in Patients With Parkinsonian Disease
L-dopa, Etoricoxib - Parkinson Disease
Phase 2RecruitingIhab Elsayed Hassan602026-01-302026-04-08
Oral Huzhang Granules for Acute Gouty Arthritis
Huzhang granule, Etoricoxib, Huzhang granule Placebo - Gouty Arthritis
Phase 2UnknownShanghai Yueyang Integrated Medicine Hospital2672020-07-012020-07-08
Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib
Etoricoxib - Pain Syndrome
Phase 2CompletedGuangdong Provincial People's Hospital1442020-03-012022-02-14
The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)
Etoricoxib 75 mg 4% DMSO Gel, Etoricoxib 75 mg 4% PG Gel, Etoricoxib 150 mg 4% DMSO Gel - Osteoarthritis Pain
Phase 1 / Phase 2CompletedOrganon and Co702013-12-232024-06-27
A Single Center 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain
Etoricoxib, followed by placebo (matching tablet, without active ingredient), Placebo (matching tablet, without active ingredient), followed by etoricoxib - Osteoarthritis
Phase 2CompletedC4Pain392012-07-012013-07-23
Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma
dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus - Advanced Melanoma
Phase 1 / Phase 2UnknownUniversity of Regensburg1362012-05-012012-06-07
Efficacy Study of Pre-emptive Etoricoxib for Postoperative Pain and Functional Outcome in Total Knee Arthroplasty
Control, Etoricoxib - Knee Osteoarthritis
Phase 2CompletedSingapore General Hospital652011-07-012017-02-10
Efficacy of Etoricoxib on Peripheral Hyperalgesia
Etoricoxib, placebo - Causalgia, Polyneuropathy
Phase 2TerminatedRuhr University of Bochum92011-02-012012-08-24
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients
Etoricoxib - HIV
Phase 2CompletedDag Kvale602010-10-012017-05-31
Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis
TNF alpha, NSAIDs and sulfasalazine - Ankylosing Spondylitis
Phase 2UnknownChung Shan Medical University3002009-11-012015-05-28
Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer
imatinib mesylate, Treosulfane, etoricoxib - Prostate Cancer
Phase 2CompletedNovartis Pharmaceuticals672007-02-012016-11-21
Modulation of the Surgical Inflammatory Response by Etoricoxib
Etoricoxib 60 mg, Placebo for Etoricoxib 60 mg - Pain, Osteoarthritis, Hip
Phase 2TerminatedUniversity of Erlangen-Nürnberg Medical School232006-05-012020-12-14
Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)
etoricoxib, Comparator: placebo, Comparator: diclofenac - Rheumatoid Arthritis
Phase 2CompletedOrganon and Co7612006-01-012022-02-09
Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083)
MK0663, etoricoxib / Duration of Treatment: 4 weeks - Bone Neoplasms
Phase 2WithdrawnOrganon and Co2004-11-012022-02-16
Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)
MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks), Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks - Osteoarthritis
Phase 2CompletedOrganon and Co11671998-06-012022-02-18

Conditions studied

Osteoarthritis (3)  ·  Arthritis, Gouty (1)  ·  Arthritis, Rheumatoid (1)  ·  Bone Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Causalgia (1)  ·  Neuralgia, Postherpetic (1)  ·  Osteoarthritis, Hip (1)  ·  Osteoarthritis, Knee (1)  ·  Pain (1)  ·  Pain, Postoperative (1)  ·  Parkinson Disease (1)  ·  Peripheral Nerve Injuries (1)  ·  Peripheral Nervous System Diseases (1)  ·  Polyneuropathies (1)

Sponsors

Organon and Co (4)  ·  C4Pain (1)  ·  Chung Shan Medical University (1)  ·  Dag Kvale (1)  ·  Guangdong Provincial People's Hospital (1)  ·  Ihab Elsayed Hassan (1)  ·  Novartis Pharmaceuticals (1)  ·  Ruhr University of Bochum (1)  ·  Shanghai Yueyang Integrated Medicine Hospital (1)  ·  Singapore General Hospital (1)  ·  University of Erlangen-Nürnberg Medical School (1)  ·  University of Regensburg (1)

Countries

Germany (4)  ·  China (1)  ·  Denmark (1)  ·  Egypt (1)  ·  Norway (1)  ·  Singapore (1)  ·  Taiwan (1)

Top investigators

Albrecht Reichle, Professor (1)  ·  Asokumar Buvanendran, MD (1)  ·  Christoph Maier, Dr.med (1)  ·  Dag Kvale, MD, PhD (1)  ·  Hans Christian Hoeck, MD PhD (1)  ·  Jia Zhou (1)  ·  Josef Zacher, MD, PhD (1)  ·  Kay Brune, MD, PhD (1)  ·  Kun Wang, MD (1)  ·  Martin Fromm, MD, PhD (1)  ·  Shi-lu Chia, MBBS (1)  ·  Wei C- C, M.D. (1)

Results publications

PMID 16321158, PMID 20052461, PMID 21905970, PMID 22337568, PMID 25886874, PMID 28464042, PMID 35365187, PMID 35724467

NIH funding

2009 (1)